ACRS Stock Summary and Trading Ideas (Aclaris Therapeutics | NASDAQ:ACRS)

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics trades on the NASDAQ stock market under the symbol ACRS.

As of April 24, 2025, ACRS stock price climbed to $1.30 with 541,381 million shares trading.

ACRS has a beta of 1.36, meaning it tends to be more sensitive to market movements. ACRS has a correlation of 0.06 to the broad based SPY ETF.

ACRS has a market cap of $139.12 million. This is considered a Micro Cap stock.

Last quarter Aclaris Therapeutics reported $9 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.17.

In the last 3 years, ACRS traded as high as $18.96 and as low as $.59.

The top ETF exchange traded funds that ACRS belongs to (by Net Assets): VTI, VXF, IWC, SBIO, DFAS.

ACRS has underperformed the market in the last year with a return of +6.6%, while the SPY ETF gained +9.1%. In the last 3 month period, ACRS fell short of the market, returning -49.0%, while SPY returned -10.4%. However, in the most recent 2 weeks ACRS has outperformed the stock market by returning +7.4%, while SPY returned -0.7%.

ACRS support price is $1.12 and resistance is $1.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRS shares will trade within this expected range on the day.